ArticleCancers2022
Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Molecular Tumor Boards clinical impact on patient care and structural features: A systematic review and meta-analysis.PLoS medicine · 2026Pooled it
- From Recommendation to Implementation: Clinical Outcomes of a Single-Center Molecular Tumor Board.Targeted oncology · 2026Article
- Optimizing Precision Oncology: Structural Frameworks for Local MTB Integration and Outcome Assessment.Medical sciences (Basel, Switzerland) · 2026Review
- Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gaps.NPJ precision oncology · 2025Article
- New Insights into Colorectal Cancer through the Lens of Precision Oncology and Personalized Medicine: Multi-Omics Helps Aging of Predisposed People.Current aging science · 2025Review
- Evolution of publicly available large language models for complex decision-making in breast cancer care.Archives of gynecology and obstetrics · 2024Article
- [Precision oncology and molecular tumor boards].Innere Medizin (Heidelberg, Germany) · 2024Review
- [Personalized medicine in oncology].Pathologie (Heidelberg, Germany) · 2024Review
- NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors-A Retrospective Molecular Tumor Board Analysis.Cancers · 2024Article
- [Precision medicine in oncology].Innere Medizin (Heidelberg, Germany) · 2024Review
- Awareness and intention-to-use of digital health applications, artificial intelligence and blockchain technology in breast cancer care.Frontiers in medicine · 2024Article
- Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors.JCO global oncology · 2024Article
- Challenging ChatGPT 3.5 in Senology-An Assessment of Concordance with Breast Cancer Tumor Board Decision Making.Journal of personalized medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncreasing knowledge of cancer biology and an expanding spectrum of molecularly targeted therapies provide the basis for precision oncology. Despite extensive gene diagnostics, previous reports indicate that less than 10% of patients benefit from this concept.
methodsWe retrospectively analyzed all patients referred to our center's Molecular Tumor Board (MTB) from 2018 to 2021. Molecular testing by next-generation sequencing (NGS) included a 67-gene panel for the detection of short-sequence variants and copy-number alterations, a 53- or 137-gene fusion panel and an ultra-low-coverage whole-genome sequencing for the detection of additional copy-number alterations outside the panel's target regions. Immunohistochemistry for microsatellite instability and PD-L1 expression complemented NGS.
resultsA total of 109 patients were referred to the MTB. In all, 78 patients received therapeutic proposals (70 based on NGS) and 33 were treated accordingly. Evaluable patients treated with MTB-recommended therapy (
conclusionThe combined focused sequencing assays detected targetable alterations in the majority of patients. Patient benefits appeared to lie in the same range as with large-scale sequencing approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.